Drug companies are abandoning the antibacterial business, citing high development costs, low return on investment and, increasingly, a nearly decade-long stalemate with the Food and Drug Administration over how to bring new antibiotics to market.
Soon, doctors fear, we could be defenseless against bacteria that can resist all existing antibiotics, which would mean more victims dead from a staph infection that drugs used to conquer easily.
Join us on our
Share this page with your friends
on your favorite social network: